Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Argenica Therapeutics Ltd ( (AU:AGN) ) has shared an announcement.
Argenica Therapeutics Limited reported a 16% reduction in losses to $1,187,221 for the half-year ended 31 December 2024, despite increased research and development costs related to their ongoing clinical trials. The company’s other income rose by 29% due to a substantial R&D tax incentive rebate, highlighting its dependence on external funding and government support for continued operations and development.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited operates in the biotechnology industry, focusing on the development of neuroprotective therapeutic drugs. The company’s primary market focus is on treatments for ischaemic stroke patients, with ongoing clinical trials for their ARG-007 drug.
YTD Price Performance: 15.87%
Average Trading Volume: 124,732
Technical Sentiment Consensus Rating: Sell
Learn more about AGN stock on TipRanks’ Stock Analysis page.
